Allianz Asset Management
NVCR icon

Allianz Asset Management’s NovoCure NVCR Stock Holding History

Allianz Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-110,500
Closed -$1.73M – 2217
2024
Q1 		$1.73M Buy
110,500
+85,200
+337% +$1.25M ﹤0.01% 1232
2023
Q4 		$378K Buy
+25,300
New +$339K ﹤0.01% 1933
2023
Q3 		– Sell
-10,477
Closed -$435K – 2242
2023
Q2 		$435K Sell
10,477
-10,302
-50% -$640K ﹤0.01% 1771
2023
Q1 		$1.25M Buy
20,779
+3,488
+20% +$279K ﹤0.01% 1591
2022
Q4 		$1.27M Sell
17,291
-3,023
-15% -$227K ﹤0.01% 1434
2022
Q3 		$1.54M Sell
20,314
-43,415
-68% -$3.39M ﹤0.01% 1317
2022
Q2 		$4.43M Sell
63,729
-8,912
-12% -$671K ﹤0.01% 1144
2022
Q1 		$6.02M Sell
72,641
-76,339
-51% -$5.62M ﹤0.01% 1156
2021
Q4 		$11.2M Buy
148,980
+41,707
+39% +$4.19M 0.01% 953
2021
Q3 		$12.5M Sell
107,273
-84,359
-44% -$12.8M 0.01% 919
2021
Q2 		$42.5M Buy
191,632
+84,466
+79% +$16.4M 0.04% 433
2021
Q1 		$14.2M Buy
107,166
+17,931
+20% +$2.84M 0.01% 725
2020
Q4 		$15.4M Sell
89,235
-112,577
-56% -$15.4M 0.02% 702
2020
Q3 		$22.5M Sell
201,812
-47,780
-19% -$3.82M 0.03% 534
2020
Q2 		$14.8M Buy
249,592
+103,263
+71% +$6.79M 0.02% 740
2020
Q1 		$9.85M Sell
146,329
-169
-0.1% -$13.4K 0.01% 858
2019
Q4 		$12.3M Sell
146,498
-36,489
-20% -$2.95M 0.01% 1016
2019
Q3 		$13.6M Sell
182,987
-52,685
-22% -$4.21M 0.01% 952
2019
Q2 		$14.9M Sell
235,672
-113,395
-32% -$5.75M 0.01% 959
2019
Q1 		$16.8M Sell
349,067
-93,820
-21% -$4.52M 0.02% 839
2018
Q4 		$14.8M Sell
442,887
-137,450
-24% -$5.03M 0.02% 885
2018
Q3 		$30.4M Sell
580,337
-118,386
-17% -$4.71M 0.03% 646
2018
Q2 		$21.9M Sell
698,723
-229,302
-25% -$6.38M 0.02% 831
2018
Q1 		$20.2M Buy
928,025
+395,316
+74% +$8.5M 0.02% 878
2017
Q4 		$10.8M Buy
+532,709
New +$10.3M 0.01% 1282

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Allianz Asset Management's NVCR Position: Q2 2024 in Review

Allianz Asset Management sold out of NovoCure (NVCR) in Q2 2024, closing a stake of 110,500 shares — an estimated $1.73M sold.

Allianz Asset Management first reported a position in NVCR in Q4 2017 and held it in 25 quarters. The position peaked at $42.5M in Q2 2021. 236 funds tracked by Wall St. Rank hold NVCR as of Q2 2024.

  • Allianz Asset Management reported no remaining NovoCure position as of Q2 2024 after selling out during the quarter.
  • Allianz Asset Management sold 110,500 NovoCure shares in Q2 2024, an estimated $1.73M.
  • Allianz Asset Management first reported a position in NovoCure in Q4 2017 and held it in 25 quarters.
  • Allianz Asset Management's NovoCure position peaked at $42.5M in Q2 2021.
  • 236 funds tracked by Wall St. Rank held NovoCure as of Q2 2024.

Based on Allianz Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.